This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease (GERD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
93
Ironwood Investigational Site
North Little Rock, Arkansas, United States
Ironwood Investigational Site
Anaheim, California, United States
Ironwood Investigational Site
Monroe, Louisiana, United States
Exploratory Endpoints - GERD Symptoms
Time frame: Change from baseline: Treatment Period (weeks 1-4) compared with 2-week (baseline) Pretreatment Period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ironwood Investigational Site
Chesterfield, Michigan, United States
Ironwood Investigational Site
Raleigh, North Carolina, United States
Ironwood Investigational Site
Cleveland, Ohio, United States
Ironwood Investigational Site
Chattanooga, Tennessee, United States
Ironwood Investigational Site
Nashville, Tennessee, United States
Ironwood Investigational Site
Logan, Utah, United States
Ironwood Investigational Site
South Ogden, Utah, United States